Waldmann T A
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 2):S37-46. doi: 10.1016/s0090-1229(05)80036-4.
Activation of resting T cells induces the synthesis of interleukin-2 (IL-2) and expression of its high-affinity receptor that involves both a 55-kDa IL-2 binding peptide identified by the anti-Tac monoclonal antibody and a 75-kDa IL-2 binding peptide associated in a receptor complex. The IL-2 receptor is proving to be an extraordinarily important therapeutic target since it is expressed by the abnormal T cells in patients with certain lymphoid malignancies or autoimmune disorders and in individuals rejecting allografts whereas it is not expressed by normal resting cells. IL-2 receptor directed monoclonal antibodies, genetically engineered humanized antibodies, and antibodies armed with toxins or radionuclides represent novel therapeutic agents for these clinical conditions.
静息T细胞的激活诱导白细胞介素-2（IL-2）的合成及其高亲和力受体的表达，该受体涉及由抗Tac单克隆抗体识别的55 kDa IL-2结合肽和在受体复合物中相关联的75 kDa IL-2结合肽。IL-2受体已被证明是一个极其重要的治疗靶点，因为它在某些淋巴恶性肿瘤或自身免疫性疾病患者的异常T细胞以及排斥同种异体移植物的个体中表达，而正常静息细胞不表达。针对IL-2受体的单克隆抗体、基因工程人源化抗体以及携带毒素或放射性核素的抗体是针对这些临床病症的新型治疗药物。
